The protein Kidney Injury Molecule 1 shows promise as a blood-based biomarker for renal cell carcinoma diagnosis and for predicting overall survival after RCC diagnosis.
Renal Cell Carcinoma
Although it may not be the last word on the topic, new research sheds light on the choice of cytoreductive nephrectomy and/or targeted therapy in patients with metastatic renal cell carcinoma.
As a physician, when choosing a new specialist to see, do you read online reviews of the provider first?
“Florida, specifically South Florida, is a very tough place to practice. There’s a fairly prominent infiltration of Medicare HMOs with a lot of obstruction to doing anything for the patient that’s necessary," says one urologist.
Other pipeline products discussed in this round-up include agents for metastatic urothelial cancer, clear cell renal cell carcinoma, and stress urinary incontinence.
Practical strategies are available to help you collaborate, not compete.
“[Researcher Arnaud Méjean, MD, PhD, has] really flipped the existing paradigm that we have in the management of advanced kidney cancer,” says Sumanta K. Pal, MD.
Retrospective analyses of data collected in a real-world study provide assurance about using nivolumab (Opdivo) to treat elderly patients with metastatic renal cell carcinoma who have failed previous therapy.
Urologists can easily miss or disregard these important aspects of contracts, which could come back to haunt them.
Noteworthy minimally invasive surgery research from AUA 2018 also included topics such as robot-assisted versus open radical cystectomy as well as minimally invasive retroperitoneal lymph node dissection in men with testis cancer.